Almirall and IRB Barcelona announce a research collaboration to discover novel molecular glue therapeutics for severe skin diseases
Pharma Mirror
JANUARY 18, 2022
These monovalent degraders offer a new avenue to induce the degradation of potentially disease-causing proteins that cannot be targeted with conventional therapeutic agents. The collaboration brings together Almirall’s scientific, dermatological, and data analysis knowledge with the expertise of the IRB Barcelona’s Targeted.
Let's personalize your content